1-(萘氧基)乙酸肼 | 24310-15-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-(萘氧基)乙酸肼
• 中文别名: 2-萘-1-氧基乙烷肼
• 英文名称: α-naphthoxyacetylhydrazine
• 英文别名: 2-(naphthalen-1-yloxy)acetohydrazide；2-(1-Naphthyloxy)acetohydrazide；2-naphthalen-1-yloxyacetohydrazide
• CAS: 24310-15-4
• 化学式: C₁₂H₁₂N₂O₂
• mdl: MFCD00156157
• 分子量: 216.239
• InChiKey: PLYHRLDIWQEXBD-UHFFFAOYSA-N

物化性质

• 沸点：
  488.7±28.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2928000090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(Naphthoxy)acetic acid hydrazide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(Naphthoxy)acetic acid hydrazide
CAS number: 24310-15-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H12N2O2
Molecular weight: 216.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(萘氧基)乙酸肼 在 三乙胺 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 3-[5-[(naphthalen-1-yloxy)methyl]-2-thioxo-1,3,4-oxadiazol-3(2H)-yl]propanenitrile
  参考文献：
  名称：

  Synthesis and antiviral evaluation of new 2,5-disubstituted 1,3,4-oxadiazole derivatives and their acyclic nucleoside analogues

  摘要：

  A number of new 5-[(naphthalen-1-yloxy)-methyl]-1,3,4-oxadiazole derivatives were synthesized. Sugar 2-[5-[(naphthalen-1-yloxy)methyl]-1,3,4-oxadiazol-2-ylthio]acetohydrazones were prepared by condensation of the hydrazide with the corresponding monosaccharides. Cyclization of the sugar hydrazones with acetic anhydride afforded the substituted oxadiazoline derivatives. The synthesized compounds displayed different degrees of antiviral activities or inhibitory actions against HCV and HIV viruses.

  DOI：

  10.1007/s00706-010-0360-y
• 作为产物：
  描述：

  2-(萘-1-基氧基)乙酸乙酯 在 一水合肼 作用下， 生成 1-(萘氧基)乙酸肼
  参考文献：
  名称：

  设计，合成，分子对接和3D-QSAR研究作为潜在抗分枝杆菌药的强力烯酰基酰基载体蛋白还原酶抑制剂

  摘要：

  为了开发抗结核分枝杆菌的先导化合物，已合成和筛选了一系列针对必需的烯酰-ACP还原酶的52种新颖的吡咯肼衍生物。采用表面对接法研究了化合物在烯酰-ACP还原酶活性位点的结合方式。结合模型表明吡咯和InhA酶之间有一个或两个氢键相互作用。高活性化合物5r（MIC 0.2μg/ mL）显示与Tyr158和NAD +的氢键相互作用以与配体PT70和三氯生相同的方式。就整体统计而言，通过数据库对齐生成的CoMFA和CoMSIA模型是最好的。CoMFA和CoMSIA模型的预测能力是使用13种化合物的测试集确定的，其预测相关系数（r pred 2）分别为0.896和0.930。

  DOI：

  10.1016/j.ejmech.2013.11.004

文献信息

• New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents
  作者：A.M. Vijesh、Arun M. Isloor、Prashanth Shetty、S. Sundershan、Hoong Kun Fun

  DOI：10.1016/j.ejmech.2012.12.057

  日期：2013.4

  their excellent therapeutic properties. Present paper describes about the synthesis of three series of new 1,2,4-triazole and benzoxazole derivatives containing substituted pyrazole moiety (11a–d, 12a–d and 13a–d). The newly synthesized compounds were characterized by spectral studies and also by C, H, N analyses. All the synthesized compounds were screened for their analgesic activity by the tail flick

  唑类化合物以其优异的治疗性能而闻名。本论文描述了含有取代的吡唑部分（11a-d，12a-d和13a-d）的三个系列的新的1,2,4-三唑和苯并恶唑衍生物的合成。通过光谱研究以及C，H，N分析对新合成的化合物进行了表征。通过甩尾法筛选所有合成的化合物的镇痛活性。新衍生物的抗菌活性也通过最小稀释浓度（MIC）通过系列稀释法进行。结果表明，化合物11c 在吡唑部分上具有2，5-二氯噻吩取代基和三唑环的化合物具有显着的止痛和抗菌活性。
• Aroylpropionic acid based 2,5-disubstituted-1,3,4-oxadiazoles: Synthesis and their anti-inflammatory and analgesic activities
  作者：Mymoona Akhter、Asif Husain、Bismillah Azad、Mohd. Ajmal

  DOI：10.1016/j.ejmech.2008.09.005

  日期：2009.6

  were tested in vivo for their anti-inflammatory activity. All the compounds tested showed anti-inflammatory activity. The compounds which showed activity comparable to the standard drug ibuprofen were screened for their analgesic, ulcerogenic and lipid peroxidation activities. Seven (3c, g, i, j, m, o, p) out of 23 new compounds showed very good anti-inflammatory activity in the carrageenan-induced rat

  本文报道了各种含1,3,4-氧杂二唑核的芳酰基丙酸衍生物的合成和生物学评估。化合物（3a - w）是通过在POCl 3的存在下用各种芳酸酰肼处理将3-芳酰基丙酸环化成1,3,4-恶二唑核合成的。新化合物的结构得到IR，1 H NMR和MS数据的支持。在体内测试了这些化合物的抗炎活性。所有测试的化合物均显示出抗炎活性。筛选显示出与标准布洛芬可比的活性的化合物的镇痛，促溃疡和脂质过氧化活性。七（3c，g在23种新化合物中，i，j，m，o，p）在角叉菜胶诱导的大鼠爪水肿试验中显示出非常好的抗炎活性，而致溃疡的作用却很小。该化合物显示出较少的致溃疡作用，还显示出丙二醛产生减少（MDA），其是脂质过氧化的副产物之一。化合物3i和o分别显示出90.50和88.88％的脚掌水肿抑制作用，69.80和66.25％的醋酸抗扭伤保护作用以及严重程度指数分别为0.7和0.65，而布洛芬的保护值分别为90.12、72
• [EN] BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT<br/>[FR] DÉRIVÉS DE BENZODIAZÉPINE, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA DÉFICIENCE COGNITIVE
  申请人：MEKONNEN BELEW

  公开号：WO2016205739A1

  公开（公告）日：2016-12-22

  This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5- containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer' s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson' s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

  这项发明涉及苯二氮卓啉衍生物，包括含有这些苯二氮卓啉衍生物的治疗有效量的组合物，以及使用这些衍生物或组合物治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法。具体而言，它涉及在需要或有风险的受试者中治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于具有或有风险患上与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症、躁郁症、肌萎缩侧索硬化（ALS）、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症谱系障碍、脆性X综合症、雷特综合症、强迫行为和物质成瘾。
• BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
  申请人：AgeneBio, Inc.

  公开号：US20180170941A1

  公开（公告）日：2018-06-21

  This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

  这项发明涉及苯二氮卓啉衍生物，包括含有这些苯二氮卓啉衍生物的治疗有效量的组合物，以及使用这些衍生物或组合物治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法。具体而言，它涉及在需要或有风险的受试者中治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于患有或有风险患有与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症、躁郁症、肌萎缩侧索硬化（ALS）、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症谱系障碍、脆性X综合症、瑞特综合症、强迫行为和物质成瘾。它还涉及在治疗与之相关的脑癌（包括脑肿瘤，例如髓母细胞瘤）和认知障碍的情况下，如本文所述使用α5含有的GABAA受体激动剂（例如，α5含有的GABAA受体正向变构调节剂）。
• Synthesis and antimicrobial activity of some heterocyclic compounds bearing benzimidazole and pyrazoline motifs
  作者：N. C. Desai、Darshan Pandya、Darshita Vaja

  DOI：10.1007/s00044-017-2040-5

  日期：2018.1

  antimicrobial activity against gram positive (S. aureus and S. pyogenes), gram negative bacteria (E. coli and P. aeruginosa), and strains of fungi (C. albicans, A. niger, and A. clavatus). Compounds were characterized by spectroscopic techniques such as 1H NMR, 13C NMR, IR, and mass spectroscopy. The newly synthesized compounds 5b, 5i and 5j, 5k showed significant antimicrobial activity against tested

  摘要一系列1-（3-（1 H-苯并咪唑-2-基）-5-芳基-4-5二氢-1 H-吡唑-1-基）-2-（萘-1-基氧基）乙酮（5a –升）被合成并评价了它们的抗微生物活性对革兰氏阳性（金黄色葡萄球菌和化脓性链球菌），革兰氏阴性细菌（大肠杆菌和绿脓杆菌），和真菌的菌株（白色念珠菌，黑曲霉，和甲。clavatus）。通过光谱技术，例如1 H NMR，13 C NMR，IR和质谱对化合物进行表征。新合成的化合物5b，5i和5j，5k显示出对测试微生物的显着抗微生物活性。 图形概要